Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reducing Sugar

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Reducing Sugar. Displaying page 1 of 1.
    EudraCT Number: 2017-004454-42 Sponsor Protocol Number: DIABMIND Start Date*: 2018-04-27
    Sponsor Name:Vall d'Hebron Research Institute
    Full Title: English A pilot interventional study to arrest the progression of cognitive decline in diabetic patients at high risk of developing Alzheimer's disease by reducing hypoglycemic events.
    Medical condition: Cognitive decline in patients affected with mild cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10012267 Dementia PT
    20.1 100000004861 10021005 Hypoglycemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016761-29 Sponsor Protocol Number: HE2013 Start Date*: 2010-05-14
    Sponsor Name:University of Birmingham
    Full Title: A 48-WEEK PHASE II, RANDOMISED, DOUBLE BLINDED PLACEBO CONTROLLED, PARALLEL-GROUP, MULTI-CENTRE TRIAL ON LIRAGLUTIDE’S SAFETY, EFFICACY AND ACTION ON LIVER HISTOLOGY AND METABOLISM IN OVERWEIGHT PA...
    Medical condition: Non-alcoholic steatohepatits (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    14.0 10019805 - Hepatobiliary disorders 10024670 Liver disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013100-32 Sponsor Protocol Number: pms.nov.001 Start Date*: 2009-12-01
    Sponsor Name:University of Exeter [...]
    1. University of Exeter
    2. Royal Devon and Exeter NHS Foundation Trust
    Full Title: Does modulating the gut hormones, incretins, modify vascular function, thereby reducing the risk of vascular complications in insulin resistant individuals?
    Medical condition: Obese (BMI equal or greater than 30) individuals at a high risk of diabetes, but without overt cardiovascular disease or taking oral hypoglycaemic, anti-hypetensive or lipid lowering therapies. Pur...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004526-72 Sponsor Protocol Number: 1 Start Date*: 2006-03-02
    Sponsor Name:Addenbrooke's NHS Trust
    Full Title: A randomised controlled study of continuous subcutaneous insulin infusion (CSII) therapy compared to conventional bolus insulin treatment in preschool aged children with Type 1 diabetes.
    Medical condition: Type 1 Diabetes Mellitus
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004191-35 Sponsor Protocol Number: GLYCO-1B Start Date*: 2019-04-12
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Evaluation of the safety and efficacy of administration of Empagliflozin in a new treatment for neutropenia in patients with Glycogen Storage Disease type 1b (GSD1b) and G6PC3 deficiency.
    Medical condition: (1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Sto...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003037-11 Sponsor Protocol Number: 21839 Start Date*: 2022-04-13
    Sponsor Name:Bayer AG
    Full Title: A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants wi...
    Medical condition: Chronic kidney disease in type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) NL (Ongoing) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004622-96 Sponsor Protocol Number: 0431-260 Start Date*: 2011-12-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabet...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IE (Completed) LT (Completed) DK (Completed) HU (Completed) BE (Completed) GB (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001641-24 Sponsor Protocol Number: PYR-311 Start Date*: 2014-09-29
    Sponsor Name:NephroGenex
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin® (pyridoxamine dihydrochloride) in Subjects With Nephropathy Due to Type ...
    Medical condition: Nephropathy Due to Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA